Evolent Health stock gains on a TransPerfect expansion

Published on 09/22/2026 at 04:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evolent Health stock closed at USD 3.68 on September 18, 2026, with a market value of USD 416.63 million. Q2 FY26 revenue reached USD 652.52 million.

EVH, US30050B1017, Illustration mit AI erstellt.

Evolent Health stock (US30050B1017) closed at USD 3.68 on September 18, 2026, with a market capitalization of USD 416.63 million and 2.55 million shares traded. The shares were still up 0.41 percent on the day, and the 52-week range ran from USD 2.10 to USD 9.63.

Deal expansion adds focus

According to Investing.com on September 21, 2026, Evolent Health selected TransPerfect for enterprise-wide telephonic interpretation services for health plan members with limited English proficiency. The update said the expanded partnership also includes centralized reporting and performance insights for NCQA accreditation, regulatory compliance, and Medicare and Medicaid requirements.

The same report said Evolent Health serves a national base of payers and providers, while TransPerfect works in more than 200 languages from offices in more than 150 cities across six continents. That makes language access and compliance a concrete operating topic for the company, not just a communications line.

Q2 figures still matter

MarketBeat said on September 20, 2026 that Evolent Health's last quarterly earnings release was on August 6, 2026, when the company reported EPS of USD 0.02, above the consensus estimate of minus USD 0.01 by USD 0.03. The same source put Q2 FY26 revenue at USD 652.52 million and called the quarterly revenue growth 46.9 percent year over year.

MarketBeat also listed a consensus price target of USD 5.96 and a Moderate Buy rating on September 20, 2026. Against the September 18 close of USD 3.68, that target sits 62.0 percent higher.

Stock stays below target

For investors, the gap between the USD 3.68 close on September 18, 2026 and the USD 5.96 consensus target remains the clearest market signal. The stock also traded 61.8 percent below the consensus target, while the 50-day range of USD 3.05 to USD 6.19 showed how sharply the shares have already moved this year.